Cabaletta Bio, Inc.

NasdaqGS:CABA 株式レポート

時価総額：US$595.2m

Cabaletta Bio マネジメント

マネジメント 基準チェック /44

Cabaletta Bioの CEO はSteven Nichtbergerで、 Jan2017年に任命され、 の在任期間は 9.33年です。 の年間総報酬は$ 2.40Mで、 27.5%給与と72.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.86%を直接所有しており、その価値は$ 5.09M 。経営陣と取締役会の平均在任期間はそれぞれ4.5年と6.3年です。

主要情報

Steven Nichtberger

最高経営責任者

US$2.4m

報酬総額

CEO給与比率27.46%
CEO在任期間9.3yrs
CEOの所有権0.9%
経営陣の平均在職期間4.5yrs
取締役会の平均在任期間6.3yrs

経営陣の近況

Recent updates

分析記事 • Mar 24

Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 27

Cabaletta Bio: Do You Buy With The Insiders?

Summary Cabaletta Bio continues to advance its engineered cell therapy pipeline targeting autoimmune diseases, maintaining cautious optimism. Recent insider share purchases have apparently bolstered confidence in CABA’s prospects following key data releases since October. At Q3 2025, CABA reported $60.2 million in cash and $99.7 million in short-term investments, supporting ongoing development. Strengths include promising pipeline updates, while risks remain around cash runway and clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Cabaletta Bio: Finding Optimism In Dire Straits

Summary Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough cash to operate for 5–6 quarters, assuming no further expense growth or additional financing. Risks include the aggressive nature of CAR T-cell therapy for non-life-threatening diseases and competition from other cell therapy approaches. With a market cap under $150 million, CABA's stock is a potential bargain if they achieve even partial success in their pipeline. Read the full article on Seeking Alpha
分析記事 • Dec 10

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 22

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Summary I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, the company’s strong cash position and lack of recent selling point to a bullish outlook. Super-positive testing results announced in mid-November would trigger significant stock gains, with the possibility of oversized returns on investment similar to 2022-23. I rate Cabaletta a Buy for a 12-month outlook, assuming a position size of less than 1% of net portfolio assets, to adequately offset greater-than-normal risk. Read the full article on Seeking Alpha
分析記事 • Sep 04

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jun 28

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Summary Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries. Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing concerns, and disappointing recent data release. Cabaletta plans to continue studies on CABA-201 for various autoimmune conditions, with the next data update due before the end of the year. The next data readout feels crucial - signs of efficacy will be greeted with a surge in share price value, but poor results could drive it back into delisting territory. There is all to play for. Read the full article on Seeking Alpha
分析記事 • May 22

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 31

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Summary Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic sclerosis, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
分析記事 • Dec 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. By way of example, Cabaletta Bio...
分析記事 • Sep 12

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
分析記事 • Jun 04

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example...
分析記事 • Feb 11

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
分析記事 • Oct 20

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Jul 07

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

CEO報酬分析

Cabaletta Bio の収益と比較して、Steven Nichtberger の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$175m

Dec 31 2025US$2mUS$660k

-US$168m

Sep 30 2025n/an/a

-US$159m

Jun 30 2025n/an/a

-US$144m

Mar 31 2025n/an/a

-US$127m

Dec 31 2024US$8mUS$646k

-US$116m

Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$597k

-US$68m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$569k

-US$53m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$4mUS$542k

-US$46m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$4mUS$516k

-US$33m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$437k

-US$22m

報酬と市場: Stevenの 総報酬 ($USD 2.40M ) は、 US市場 ($USD 2.64M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Stevenの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Steven Nichtberger (64 yo)

9.3yrs
在職期間
US$2,401,555
報酬

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Steven Nichtberger
Co-Founder9.3yrsUS$2.40m0.86%
$ 5.1m
David Chang
Chief Medical Officer6.9yrsUS$1.24m0.0054%
$ 32.1k
Gwendolyn Binder
President of Science & Technologyno dataUS$1.26m0.019%
$ 114.3k
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno dataデータなしデータなし
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno dataデータなしデータなし
Anup Marda
Chief Financial Officer7.3yrsUS$1.53mデータなし
Qing Yuan
Chief Technology Officer1.9yrsデータなしデータなし
Samik Basu
Chief Scientific Officer4.5yrsデータなしデータなし
Michael Gerard
General Counsel & Secretary4.7yrsデータなしデータなし
Heather Harte-Hall
Chief Compliance Officer4.5yrsデータなしデータなし
Nicolette Sherman
Chief Human Resources Officer1.5yrsデータなしデータなし
Arun Das
Chief Business Officer4.3yrsデータなしデータなし
4.5yrs
平均在職期間
52yo
平均年齢

経験豊富な経営陣: CABAの経営陣は 経験豊富 であると考えられます ( 4.5年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Steven Nichtberger
Co-Founder9.3yrsUS$2.40m0.86%
$ 5.1m
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno dataデータなしデータなし
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno dataデータなしデータなし
Richard Henriques
Independent Director7.3yrsUS$152.17k0%
$ 0
Carl June
Member of Scientific Advisory Board5.8yrsデータなしデータなし
Mark Simon
Independent Director7.6yrsUS$140.91k0.095%
$ 562.9k
Scott Brun
Independent Director4.9yrsUS$136.84k0%
$ 0
Iain McInnes
Member of Scientific Advisory Board6.3yrsデータなしデータなし
Jay Siegel
Member of Scientific Advisory Boardno dataデータなしデータなし
Georg Schett
Member of Scientific Advisory Board4.3yrsデータなしデータなし
Shawn Tomasello
Independent Director2.8yrsUS$119.17k0.014%
$ 83.0k
Catherine Bollard
Independent Director7.1yrsUS$145.57k0.0033%
$ 19.7k
6.3yrs
平均在職期間
64yo
平均年齢

経験豊富なボード: CABAの 取締役会 は 経験豊富 であると考えられます ( 6.3年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/24 19:10
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cabaletta Bio, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15

アナリスト機関
Joshua SchimmerCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc
Joshua SchimmerEvercore ISI